Mark Dysinger

Title: Mark Dysinger: Innovator in Complement Protein Quantitation

Introduction

Mark Dysinger is a notable inventor based in Killingworth, CT (US). He has made significant contributions to the field of biochemistry, particularly in the quantitation of complement proteins. With a total of 2 patents, Dysinger's work has implications for both research and clinical applications.

Latest Patents

Dysinger's latest patents include innovative methods for quantitating unbound C5 and C5a complement proteins. The first patent describes a method for quantitating free (unbound) human C5 complement protein from a sample. This involves binding biotinylated anti-C5 capture antibody to streptavidin-coated particles, capturing the free C5 in the sample, detecting the captured free C5, and quantitating it using laser-induced fluorescence detection. This method is performed in a Gyros Bioaffy 200 CD in a Gyrolab xPlore or a Gyrolab XP instrument. The second patent outlines a similar method for quantitating free (unbound) human C5a complement protein, with the additional step of removing human C5 from the sample prior to quantitation.

Career Highlights

Mark Dysinger is currently employed at Alexion Pharmaceuticals, Inc., where he continues to advance his research in complement proteins. His work is crucial for understanding immune responses and developing therapeutic strategies.

Collaborations

Dysinger collaborates with notable colleagues, including Mark Ma and Bruce A Andrien, Jr. Their combined expertise enhances the innovative research environment at Alexion Pharmaceuticals.

Conclusion

Mark Dysinger's contributions to the field of complement protein quantitation exemplify the impact of innovative research in biochemistry. His patents reflect a commitment to advancing scientific knowledge and improving clinical practices.